FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171460614> ?p ?o ?g. }

• W2171460614 endingPage "33" @default.
• W2171460614 startingPage "2025" @default.
• W2171460614 abstract "High levels of glucagon-like peptide-1 (GLP-1) receptor expression in human insulinomas and gastrinomas provide an attractive target for imaging, therapy, and intraoperative tumor localization, using receptor-avid radioligands. The goal of this study was to establish a tumor model for GLP-1 receptor targeting and to use a newly designed exendin-4-DTPA (DTPA is diethylenetriaminepentaacetic acid) conjugate for GLP-1 receptor targeting.Exendin-4 was modified C-terminally with Lys(40)-NH(2), whereby the lysine side chain was conjugated with Ahx-DTPA (Ahx is aminohexanoic acid). The GLP-1 receptor affinity (50% inhibitory concentration [IC(50)] value) of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 as well as the GLP-1 receptor density in tumors and different organs of Rip1Tag2 mice were determined. Rip1Tag2 mice are transgenic mice that develop insulinomas in a well-defined multistage tumorigenesis pathway. This animal model was used for biodistribution studies, pinhole SPECT/MRI, and SPECT/CT. Peptide stability, internalization, and efflux studies were performed in cultured beta-tumor cells established from tumors of Rip1Tag2 mice.The GLP-1 receptor affinity of [Lys(40)(Ahx-DTPA)NH(2)]exendin-4 was found to be 2.1 +/- 1.1 nmol/L (mean +/- SEM). Because the GLP-1 receptor density in tumors of Rip1Tag2 mice was very high, a remarkably high tumor uptake of 287 +/- 62 %IA/g (% injected activity per gram tissue) was found 4 h after injection. This resulted in excellent tumor visualization by pinhole SPECT/MRI and SPECT/CT. In accordance with in vitro data, [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 uptake in Rip1Tag2 mice was also found in nonneoplastic tissues such as pancreas and lung. However, lung and pancreas uptake was distinctly lower compared with that of tumors, resulting in a tumor-to-pancreas ratio of 13.6 and in a tumor-to-lung ratio of 4.4 at 4 h after injection. Furthermore, in vitro studies in cultured beta-tumor cells demonstrated a specific internalization of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4, whereas peptide stability studies indicated a high metabolic stability of the radiopeptide in beta-tumor cells and human blood serum.The high density of GLP-1 receptors in insulinomas as well as the high specific uptake of [Lys(40)(Ahx-DTPA-(111)In)NH(2)]exendin-4 in the tumor of Rip1Tag2 mice indicate that targeting of GLP-1 receptors in insulinomas may become a useful imaging method to localize insulinomas in patients, either preoperatively or intraoperatively. In addition, Rip1Tag2 transgenic mice represent a suitable animal tumor model for GLP-1 receptor targeting." @default.
• W2171460614 created "2016-06-24" @default.
• W2171460614 creator A5022226042 @default.
• W2171460614 creator A5023353633 @default.
• W2171460614 creator A5042300545 @default.
• W2171460614 creator A5061906450 @default.
• W2171460614 creator A5066158692 @default.
• W2171460614 creator A5066412001 @default.
• W2171460614 creator A5072271891 @default.
• W2171460614 creator A5072560130 @default.
• W2171460614 creator A5083154878 @default.
• W2171460614 creator A5086720156 @default.
• W2171460614 date "2006-12-01" @default.
• W2171460614 modified "2023-10-17" @default.
• W2171460614 title "[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting." @default.
• W2171460614 cites W1907629755 @default.
• W2171460614 cites W1933901479 @default.
• W2171460614 cites W1965895443 @default.
• W2171460614 cites W1966769262 @default.
• W2171460614 cites W1994118792 @default.
• W2171460614 cites W2001328936 @default.
• W2171460614 cites W2004507412 @default.
• W2171460614 cites W2005907891 @default.
• W2171460614 cites W2011187030 @default.
• W2171460614 cites W2016356824 @default.
• W2171460614 cites W2017518223 @default.
• W2171460614 cites W2020874999 @default.
• W2171460614 cites W2021601185 @default.
• W2171460614 cites W2042875582 @default.
• W2171460614 cites W2045681528 @default.
• W2171460614 cites W2045991184 @default.
• W2171460614 cites W2059777719 @default.
• W2171460614 cites W2065361341 @default.
• W2171460614 cites W2080128749 @default.
• W2171460614 cites W2080916065 @default.
• W2171460614 cites W2088147866 @default.
• W2171460614 cites W2089723533 @default.
• W2171460614 cites W2107348004 @default.
• W2171460614 cites W2107387649 @default.
• W2171460614 cites W2108613323 @default.
• W2171460614 cites W2114802801 @default.
• W2171460614 cites W2138185928 @default.
• W2171460614 cites W2142903571 @default.
• W2171460614 cites W2160203786 @default.
• W2171460614 cites W2161146215 @default.
• W2171460614 cites W2164003774 @default.
• W2171460614 cites W2164280947 @default.
• W2171460614 cites W2170048668 @default.
• W2171460614 cites W2239520447 @default.
• W2171460614 cites W2278389458 @default.
• W2171460614 cites W251243753 @default.
• W2171460614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17138746" @default.
• W2171460614 hasPublicationYear "2006" @default.
• W2171460614 type Work @default.
• W2171460614 sameAs 2171460614 @default.
• W2171460614 citedByCount "54" @default.
• W2171460614 countsByYear W21714606142012 @default.
• W2171460614 countsByYear W21714606142013 @default.
• W2171460614 countsByYear W21714606142014 @default.
• W2171460614 countsByYear W21714606142015 @default.
• W2171460614 countsByYear W21714606142016 @default.
• W2171460614 countsByYear W21714606142017 @default.
• W2171460614 countsByYear W21714606142018 @default.
• W2171460614 countsByYear W21714606142019 @default.
• W2171460614 countsByYear W21714606142020 @default.
• W2171460614 countsByYear W21714606142021 @default.
• W2171460614 countsByYear W21714606142023 @default.
• W2171460614 crossrefType "journal-article" @default.
• W2171460614 hasAuthorship W2171460614A5022226042 @default.
• W2171460614 hasAuthorship W2171460614A5023353633 @default.
• W2171460614 hasAuthorship W2171460614A5042300545 @default.
• W2171460614 hasAuthorship W2171460614A5061906450 @default.
• W2171460614 hasAuthorship W2171460614A5066158692 @default.
• W2171460614 hasAuthorship W2171460614A5066412001 @default.
• W2171460614 hasAuthorship W2171460614A5072271891 @default.
• W2171460614 hasAuthorship W2171460614A5072560130 @default.
• W2171460614 hasAuthorship W2171460614A5083154878 @default.
• W2171460614 hasAuthorship W2171460614A5086720156 @default.
• W2171460614 hasConcept C116569031 @default.
• W2171460614 hasConcept C139770010 @default.
• W2171460614 hasConcept C170493617 @default.
• W2171460614 hasConcept C185592680 @default.
• W2171460614 hasConcept C202751555 @default.
• W2171460614 hasConcept C2777807558 @default.
• W2171460614 hasConcept C2779281246 @default.
• W2171460614 hasConcept C2989005 @default.
• W2171460614 hasConcept C2993559085 @default.
• W2171460614 hasConcept C502942594 @default.
• W2171460614 hasConcept C55493867 @default.
• W2171460614 hasConcept C71924100 @default.
• W2171460614 hasConceptScore W2171460614C116569031 @default.
• W2171460614 hasConceptScore W2171460614C139770010 @default.
• W2171460614 hasConceptScore W2171460614C170493617 @default.
• W2171460614 hasConceptScore W2171460614C185592680 @default.
• W2171460614 hasConceptScore W2171460614C202751555 @default.
• W2171460614 hasConceptScore W2171460614C2777807558 @default.
• W2171460614 hasConceptScore W2171460614C2779281246 @default.
• W2171460614 hasConceptScore W2171460614C2989005 @default.

• next